Adverum Biotechnologies, Inc.

NasdaqCM:ADVM Stock Report

Market Cap: US$157.3m

Adverum Biotechnologies Valuation

Is ADVM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ADVM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ADVM?

Key metric: As ADVM barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ADVM. This is calculated by dividing ADVM's market cap by their current book value.
What is ADVM's PB Ratio?
PB Ratio1x
BookUS$144.12m
Market CapUS$157.27m

Price to Book Ratio vs Peers

How does ADVM's PB Ratio compare to its peers?

The above table shows the PB ratio for ADVM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.6x
ANIX Anixa Biosciences
4.6x9.5%US$99.8m
PGEN Precigen
5.9x64.1%US$263.8m
AVTX Avalo Therapeutics
6.7x-17.9%US$140.2m
INO Inovio Pharmaceuticals
1.3x36.4%US$128.5m
ADVM Adverum Biotechnologies
1x-16.9%US$157.3m

Price-To-Book vs Peers: ADVM is good value based on its Price-To-Book Ratio (1x) compared to the peer average (4.6x).


Price to Book Ratio vs Industry

How does ADVM's PB Ratio compare vs other companies in the US Biotechs Industry?

58 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2xn/aUS$528.60m
IMAB I-Mab
0.4x1.9%US$86.32m
MGX Metagenomi
0.3x-22.7%US$78.96m
MURA Mural Oncology
0.3x17.6%US$59.97m
ADVM 1.0xIndustry Avg. 1.9xNo. of Companies75PB01.63.24.86.48+
58 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ADVM is good value based on its Price-To-Book Ratio (1x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is ADVM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ADVM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ADVM's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ADVM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$7.25
US$29.71
+309.9%
36.1%US$40.00US$10.00n/a7
Nov ’25US$7.41
US$30.00
+304.9%
34.0%US$40.00US$12.00n/a7
Oct ’25US$6.59
US$30.00
+355.2%
34.0%US$40.00US$12.00n/a7
Sep ’25US$6.94
US$30.00
+332.3%
34.0%US$40.00US$12.00n/a7
Aug ’25US$7.57
US$33.57
+343.5%
40.7%US$60.00US$15.00n/a7
Jul ’25US$6.97
US$33.86
+385.8%
38.4%US$60.00US$20.00n/a7
Jun ’25US$7.92
US$35.33
+346.1%
38.2%US$60.00US$20.00n/a6
May ’25US$9.79
US$35.33
+260.9%
38.2%US$60.00US$20.00n/a6
Apr ’25US$13.89
US$40.00
+188.0%
31.6%US$60.00US$20.00n/a5
Mar ’25US$19.70
US$42.00
+113.2%
23.3%US$60.00US$30.00n/a5
Feb ’25US$11.90
US$38.00
+219.3%
34.9%US$60.00US$20.00n/a5
Jan ’25US$7.53
US$38.00
+404.8%
34.9%US$60.00US$20.00n/a5
Dec ’24US$8.28
US$38.00
+359.2%
34.9%US$60.00US$20.00n/a5
Nov ’24US$9.13
US$38.00
+316.4%
34.9%US$60.00US$20.00US$7.415
Oct ’24US$15.00
US$42.50
+183.3%
25.6%US$60.00US$30.00US$6.594
Sep ’24US$18.00
US$42.50
+136.1%
25.6%US$60.00US$30.00US$6.944
Aug ’24US$22.30
US$43.33
+94.3%
28.8%US$60.00US$30.00US$7.573
Jul ’24US$15.90
US$40.00
+151.6%
35.4%US$60.00US$30.00US$6.973
Jun ’24US$11.40
US$40.00
+250.9%
35.4%US$60.00US$30.00US$7.923
May ’24US$8.10
US$32.50
+301.2%
50.4%US$60.00US$20.00US$9.794
Apr ’24US$7.17
US$32.50
+353.0%
50.4%US$60.00US$20.00US$13.894
Mar ’24US$7.50
US$36.67
+388.9%
46.4%US$60.00US$20.00US$19.703
Feb ’24US$6.71
US$36.67
+446.2%
46.4%US$60.00US$20.00US$11.903
Jan ’24US$5.80
US$36.67
+532.7%
46.4%US$60.00US$20.00US$7.533
Dec ’23US$6.78
US$36.67
+440.8%
46.4%US$60.00US$20.00US$8.283
Nov ’23US$8.76
US$45.00
+413.8%
32.7%US$60.00US$25.00US$9.133

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies